Table 2

Induction of EAE and Spontaneous Recovery*

B10.PLB10.PLμMTP**
Incidence  16/19  19/22   
Onset day of EAE  16.2 ± 0.68 (13–21)§  15.4 ± 0.92 (9–25)  P = NS 
Maximum disease severity  2.47 ± 0.21 (1-3.5)  2.66 ± 0.20 (1.5-5)  P = NS 
Disease at day 40  0.44 ± 0.14 (0-1)  2.03 ± 0.20 (1–5)  P = 0.01 
B10.PLB10.PLμMTP**
Incidence  16/19  19/22   
Onset day of EAE  16.2 ± 0.68 (13–21)§  15.4 ± 0.92 (9–25)  P = NS 
Maximum disease severity  2.47 ± 0.21 (1-3.5)  2.66 ± 0.20 (1.5-5)  P = NS 
Disease at day 40  0.44 ± 0.14 (0-1)  2.03 ± 0.20 (1–5)  P = 0.01 
*

 B10.PL and B10.PLμMT female mice were inoculated with MBP Ac1-11 emulsified in CFA and observed for signs of EAE.  

 3/19 B10.PL mice and 3/22 B10.PLμMT mice inoculated with MBP Ac1-11 did not show signs of EAE. These animals were not included in the following statistics (§ **). (   ) Mean ± SE (range). EAE disease severity was graded in a scale 0–5: 0, no disease; 1, limp tail; 2, hind limb paresis; 3, hind limb paralysis; 4, hind limb and fore limb paralysis; 5, death. All animals were graded daily through day 40.  

**

Student's t test using 34 degrees of freedom was applied to the two groups. P ⩽0.01 is considered significant.  

or Create an Account

Close Modal
Close Modal